section name header

Pronunciation

per-FEN-a-zeen

Classifications

Therapeutic Classification: antiemetics, antipsychotics (conventional)

Pharmacologic Classification: phenothiazines

Indications

BEERS REMS


Action

  • Alters the effects of dopamine in the CNS.
  • Possesses significant anticholinergic and alpha-adrenergic blocking activity.
  • Blocks dopamine in the chemoreceptor trigger zone (CTZ).
Therapeutic effects:
  • Diminished signs and symptoms of psychoses.
  • Decreased nausea and vomiting.

Pharmacokinetics

Absorption: 20% absorbed following oral administration.

Distribution: Widely distributed, high concentrations in the CNS.

Protein Binding: 90%.

Metabolism/Excretion: Mostly metabolized by the liver via the CYP2D6 isoenzyme;the CYP2D6 isoenzyme exhibits genetic polymorphism; 7% of population may be poor metabolizers and may have significantly perphenazine concentrations and an risk of adverse effects.

Half-Life: 8.4–12.3 hr.

Time/Action Profile

(antipsychotic effect)
ROUTEONSETPEAKDURATION
PO2–6 hrunknown6–12 hr



Optimal antipsychotic response may not occur for several wk.



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: hypotension, tachycardia

Derm: photosensitivity, pigment changes, rash

EENT: blurred vision, dry eyes, lens opacities

Endo: galactorrhea, amenorrhea

GI: constipation, dry mouth, anorexia, ileus

GU: urinary retention, urine discoloration

Hemat: AGRANULOCYTOSIS, leukopenia

Metab: hyperthermia, weight gain

Neuro: extrapyramidal reactions, NEUROLEPTIC MALIGNANT SYNDROME, sedation, tardive dyskinesia

Misc: allergic reactions

Interactions

Drug-drug:

Drug-Natural Products:

Route/Dosage

Schizophrenia

Nausea/Vomiting

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Trilafon